Lannett Co Inc Shares Outstanding 2006-2019 | LCI

Lannett Co Inc shares outstanding from 2006 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Lannett Co Inc Annual Shares Outstanding
(Millions of Shares)
2019 38
2018 38
2017 37
2016 37
2015 37
2014 35
2013 29
2012 28
2011 27
2010 25
2009 25
2008 24
2007 24
2006 24
2005 24
Lannett Co Inc Quarterly Shares Outstanding
(Millions of Shares)
Q2 2019 41
Q1 2019 38
Q4 2019 38
Q3 2019 39
Q2 2018 39
Q1 2018 38
Q4 2018 38
Q3 2018 38
Q2 2017 38
Q1 2017 38
Q4 2017 37
Q3 2017 38
Q2 2016 38
Q1 2016 37
Q4 2016 37
Q3 2016 36
Q2 2015 37
Q1 2015 37
Q4 2015 37
Q3 2015 37
Q2 2014 37
Q1 2014 37
Q4 2014 35
Q3 2014 37
Q2 2013 36
Q1 2013 30
Q4 2013 29
Q3 2013 29
Q2 2012 28
Q1 2012 28
Q4 2012 28
Q3 2012 29
Q2 2011 29
Q1 2011 29
Q4 2011 27
Q3 2011 28
Q2 2010 26
Q1 2010 25
Q4 2010 25
Q3 2010 25
Q2 2009 25
Q1 2009 25
Q4 2009 25
Q3 2009 25
Q2 2008 25
Q1 2008 24
Q4 2008 24
Q3 2008 24
Q2 2007 24
Q1 2007 24
Q4 2007 24
Q3 2007 24
Q2 2006 24
Q1 2006 24
Q4 2006 24
Q3 2006 24
Q2 2005 24
Q1 2005 24
Q4 2005 24
Q3 2005 24
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.378B $0.655B
Lannett Company manufactures and distributes high quality affordable generic medications that are the therapeutic equivalent of the brand-name pharmaceuticals. Their portfolio consists of numerous products across a wide range of therapeutic areas. Lannett believes that their ability to select viable products for development, efficiently develop such products, including obtaining any applicable regulatory approvals, vertically integrate themselves into certain specialty markets and achieve economies in production are all critical for their success in the generic pharmaceutical industry in which they operate. Lannett Company, Inc., continues to dedicate significant capital toward developing new products as they believe their success is linked to their ability to continually introduce new generic products into the marketplace.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $65.726B 38.02
Takeda Pharmaceutical (TAK) Japan $56.981B 10.10
Astellas Pharma (ALPMY) Japan $30.920B 15.44
Eisai (ESALY) Japan $22.211B 42.82
UCB SA (UCBJF) Belgium $18.867B 0.00
Grifols, S.A (GRFS) Spain $17.010B 22.29
Merck (MKGAF) Germany $16.730B 22.83
Ono Pharmaceutical (OPHLF) Japan $9.450B 20.20
Neurocrine Biosciences (NBIX) United States $8.946B 248.54
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $8.449B 0.00
Catalent (CTLT) United States $8.188B 33.69
Ionis Pharmaceuticals (IONS) United States $8.032B 16.27
Jazz Pharmaceuticals (JAZZ) Ireland $7.403B 9.46
IPSEN SA ADR (IPSEY) France $5.891B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.877B 0.00
Orion OYJ (ORINY) Finland $5.871B 30.12
STADA ARZNEIMI (STDAF) Germany $5.543B 0.00
Hypermarcas (HYPMY) Brazil $5.368B 16.33
United Therapeutics (UTHR) United States $5.062B 0.00
Nektar Therapeutics (NKTR) United States $3.934B 0.00
FibroGen (FGEN) United States $3.803B 111.77
Evotec AG (EVTCY) Germany $3.797B 61.27
Arrowhead Pharmaceuticals (ARWR) United States $3.699B 68.66
Sage Therapeutics (SAGE) United States $3.479B 0.00
PTC Therapeutics (PTCT) United States $3.383B 0.00
Taro Pharmaceutical Industries (TARO) Israel $2.822B 11.42
ChemoCentryx (CCXI) United States $2.728B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $2.153B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.983B 54.23
Xencor (XNCR) United States $1.890B 77.49
Heron Therapeutics (HRTX) United States $1.885B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.784B 21.68
Tilray (TLRY) Canada $1.738B 0.00
Corcept Therapeutics (CORT) United States $1.519B 17.04
USANA Health Sciences (USNA) United States $1.456B 15.22
CLINIGEN GP (CLIGF) United Kingdom $1.392B 0.00
Endo (ENDP) Ireland $1.361B 2.50
Theravance Biopharma (TBPH) Cayman Islands $1.334B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.328B 9.06
Zogenix (ZGNX) United States $1.279B 0.00
Akebia Therapeutics (AKBA) United States $1.188B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.025B 31.75
Portola Pharmaceuticals (PTLA) United States $1.016B 0.00
Aerie Pharmaceuticals (AERI) United States $0.940B 0.00
Karyopharm Therapeutics (KPTI) United States $0.929B 0.00
Radius Health (RDUS) United States $0.881B 0.00
Collegium Pharmaceutical (COLL) United States $0.796B 0.00
ImmunoGen (IMGN) United States $0.762B 0.00
Molecular Templates (MTEM) United States $0.633B 0.00
Flexion Therapeutics (FLXN) United States $0.620B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.548B 0.00
TherapeuticsMD (TXMD) United States $0.515B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.506B 61.38
Ardelyx (ARDX) United States $0.501B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.450B 19.40
Innate Pharma SA (IPHYF) France $0.446B 0.00
Translate Bio (TBIO) United States $0.441B 0.00
Organogenesis Holdings (ORGO) United States $0.424B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.407B 0.00
Calithera Biosciences (CALA) United States $0.404B 0.00
DURECT (DRRX) United States $0.402B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.398B 0.00
Siga Technologies (SIGA) United States $0.371B 8.46
Rigel Pharmaceuticals (RIGL) United States $0.369B 0.00
Harpoon Therapeutics (HARP) United States $0.362B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.357B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.356B 0.00
Recro Pharma (REPH) United States $0.355B 0.00
Indivior (INVVY) United States $0.353B 2.10
Rafael Holdings (RFL) United States $0.323B 0.00
Concert Pharmaceuticals (CNCE) United States $0.321B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.316B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.309B 0.00
OptiNose (OPTN) United States $0.288B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.248B 0.00
Ocular Therapeutix (OCUL) United States $0.247B 0.00
IMV INC (IMV) Canada $0.242B 0.00
MEI Pharma (MEIP) United States $0.242B 0.00
KalVista Pharmaceuticals (KALV) United States $0.237B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.196B 0.00
Nature's Sunshine Products (NATR) United States $0.194B 33.47
Taiwan Liposome (TLC) Taiwan $0.194B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.194B 0.00
Jounce Therapeutics (JNCE) United States $0.191B 2.56
Galmed Pharmaceuticals (GLMD) Israel $0.126B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.122B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.118B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.114B 0.00
CannTrust Holdings (CTST) Canada $0.113B 0.00
Xeris Pharmaceuticals (XERS) United States $0.111B 0.00
Otonomy (OTIC) United States $0.106B 0.00
Redhill Biopharma (RDHL) Israel $0.103B 0.00
Aquestive Therapeutics (AQST) United States $0.102B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.094B 0.00
CV Sciences (CVSI) United States $0.080B 0.00
Champions Oncology (CSBR) United States $0.080B 0.00
MediWound (MDWD) Israel $0.079B 0.00
Neos Therapeutics (NEOS) United States $0.078B 0.00
Infinity Pharmaceuticals (INFI) United States $0.076B 0.00
Onconova Therapeutics (ONTX) United States $0.072B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.067B 20.05
Entasis Therapeutics Holdings (ETTX) United States $0.067B 0.00
CTI BioPharma (CTIC) United States $0.063B 0.00
Nivalis Therapeutics (ALPN) United States $0.063B 0.00
SCYNEXIS (SCYX) United States $0.061B 0.00
VAXART, INC (VXRT) United States $0.061B 0.00
Aclaris Therapeutics (ACRS) United States $0.059B 0.00
RENEURON GP (RNUGF) United Kingdom $0.059B 0.00
IsoRay (ISR) United States $0.056B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.053B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.052B 0.00
Natural Alternatives (NAII) United States $0.050B 22.81
AgeX Therapeutics (AGE) United States $0.047B 0.00
Forward Pharma (FWP) Denmark $0.047B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.046B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.046B 0.00
Iterum Therapeutics (ITRM) Ireland $0.043B 0.00
PolarityTE (PTE) United States $0.042B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.038B 0.00
Mannatechorporated (MTEX) United States $0.036B 0.00
Jaguar Animal Health (JAGX) United States $0.035B 0.00
ElectroCore (ECOR) United States $0.030B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.028B 0.00
PharmAthene (ALT) United States $0.027B 0.00
Biomerica (BMRA) United States $0.027B 0.00
Vical (BBI) United States $0.027B 0.00
Cardiome Pharma (CORV) Canada $0.026B 0.00
China SXT Pharmaceuticals (SXTC) China $0.026B 0.00
India Globalization Capital (IGC) United States $0.022B 0.00
ProPhase Labs (PRPH) United States $0.020B 0.00
Lipocine (LPCN) United States $0.020B 0.00
Bio-Path Holdings (BPTH) United States $0.018B 0.00
Regulus Therapeutics (RGLS) United States $0.017B 0.00
Shineco (TYHT) China $0.017B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.017B 0.00
Heat Biologics (HTBX) United States $0.015B 0.00
Novan (NOVN) United States $0.014B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.013B 0.00
HANCOCK JAFFE (HJLI) United States $0.012B 0.00
Cyanotech (CYAN) United States $0.012B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.010B 0.00
Hemispherx BioPharma (AIM) United States $0.009B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.008B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.008B 0.00
Xenetic Biosciences (XBIO) United States $0.004B 0.00
Flex Pharma (SLRX) United States $0.004B 0.00
Can-Fite Biopharma (CANF) Israel $0.002B 0.00
RXi Pharmaceuticals (PHIO) United States $0.002B 0.00
Midatech Pharma (MTP) United Kingdom $0.002B 0.00